Harald Hampel, MD, PhD, MSc’s Post

Interesting post and link to a journal article including blood based biomarkers in clinical trials for Alzheimer's disease therapies from Harald Hampel, MD, PhD, MSc. University of Otago researchers had Harald's biomarker shopping list from an earlier Alzheimer's conference presentation on their mind when they started looking for new blood based Alzheimer's biomarkers. #OtagoInnovation #ADdx Check this out Jo Williams, Warren Tate, Wickliffe Abraham and Diane Guevremont

#medicine #medicalsciences #healthcare #neurology #neuroscience In #neuroinflammatory diseases, systemic (blood-borne) leukocytes invade the central nervous system (CNS) and lead to tissue damage. A causal relationship between neuroinflammatory diseases and dysregulated #cytokine networks is well established across several preclinical models. 

A very interesting case record of the Massachusetts General Hospital of a 78-year-old woman with rapidly progressive dementia, published in the New England Journal of Medicine. Read more: https://lnkd.in/eV5zUQnw NEJM Group #neuroscience #neurology #casereport #caserecord #brain #diagnosis #detection #differentiadiagnosis #classification #medicine #pathology #biomarkers #neuroimaging #genetics #dementia #cognitivedecline #neurologicaldisorders #neurodegenerativediseases #neuroinflammation #immunology #neuroimmunology #memory #alzheimer #alzheimersdisease #brainhealth #precisionmedicine #cognition #encephalitis #autoimmune #autoimmunediseases #paraneoplastic #braintumor #oncology Mechanisms Underlying ANNA-1 Paraneoplastic Autoimmune Encephalitis

Fascinating read on Alzheimer's & Dementia research being done demonstrating that blood biomarkers can provide predictive insights into disease. #predictiveanalytics #alzheimers #dementia #patientsfirst #researchadvances https://lnkd.in/g-dgQQCD

Alcohol consumers with liver pathology rarely display α-synuclein pathology A study examining postmortem brain and liver tissue from 100 individuals found a negative correlation between alcohol-induced liver damage and α-synuclein pathology in the brain. Individuals with severe liver damage were more likely to have Alzheimer's type II astrocytes, but dementia was less common in this group. These findings suggest that alcohol consumption may protect against Parkinson's disease although the sample size is small. This study should be replicated in other populations as well. The article was published in Acta Neuropathologica: https://lnkd.in/eR7AYj9B #genetics #genomics #precisionmedicine #genomicmedicine #brain #neurology #neurodegeneration #neuroscience #alzheimer #parkinson #als #ftd #alcohol #addiction #liver #hepatology #clinicalresearch #biomarkers #biotechnology #innovation #research #science #sciencecommunication

Alcohol appears to have dose-dependent effects. Excess intake is clearly detrimental, but use and abuse are entirely different. The latest recommendation in oncology is that zero intake is best. In the real world, people have more than cancer to consider though. Add the study below that shows less abnormal protein aggregation in the brain to your alcohol pro/con list. Perhaps we will be able to individualize our recommendations for alcohol intake someday.

AD diagnostic testing is a hot topic especially in light of recent Kinsula approval. Besides the new paper below, PT217 is also listed in the revised criteria for diagnosis and staging of Alzheimer's disease by Alzheimer's Association Workgroup. https://lnkd.in/gqEJxDiK “Early-changing Core 1 biomarkers (amyloid positron emission tomography [PET], approved cerebrospinal fluid biomarkers, and accurate plasma biomarkers [especially phosphorylated tau 217]) map onto either the amyloid beta or AD tauopathy pathway.” “Thus, our definition of Core 1 plasma tests that suffice as standalone diagnostic tests for AD is those with a minimum accuracy of 90% to detect abnormal amyloid PET in the intended-use population, or, more simply, plasma tests whose diagnostic performance is equivalent to that of approved CSF assays (Box 2). Our position is that BBM that achieve this diagnostic performance benchmark should be considered on equal footing with established PET and CSF biomarkers for diagnosis of AD.” Find out more about plasma PT217 from Mayo Clinic Labs that has an overall accuracy of 93% here: https://lnkd.in/gaAqkiBb #Alzheimer #Diagnostic #PlasmaBiomarkers #PhosphoTau217 #MildCognitiveImpairement #AmyloidPathology #Guidelines #MayoClinicLabs

Our international neurophysiology research consortium has published a summary of the most recent evidence suggesting a contribution of parvalbumin-positive (PV+) interneuron dysfunction to the pathophysiology of a spectrum of brain proteinopathies and primary neurodegenerative diseases, such as Alzheimer's disease, Frontotemporal Dementia (FTD), and Dementia with Lewy bodies (DLB). Specifically, we focused on the interplay between misfolded protein accumulation and this specific subtype of inhibitory interneurons whose functional alteration leads to network hypersynchrony, cortical hyperexcitability, and gamma rhythm disruption, with the aim of integrating these findings into a coherent pathophysiological framework for each disease. Highlights: • Parvalbumin-positive interneurons regulate cortical excitation/inhibition balance. • Their dysfunction results in cortical hyperexcitability and gamma rhythm disruption. • PV+ interneurons are impaired in AD; their restoration improved patients’ cognition. • Albeit with some differences, PV+ cells are also impaired in FTD and DLB mouse models. • Their dysfunction represents a common pathophysiological aspect across etiologies. Learn more: https://lnkd.in/er5gp3q6 Elsevier #neuroscience #neurology #precisionmedicine #neurophysiology #EEG #neuroimaging #systemstheory #systemsthinking #brainfunction #brainhealth #neurodegeneration #neurodegenerativediseases #neurologicaldisorders #dementia #cognitivedecline #alzheimer #alzheimersdisease #FTD #FrontotemporalDementia #DLB #DementiawithLewybodies #cortex #neurons #interneuron #neuron #parvalbumin #biomarkers Figure legend: The pathophysiological framework of PV+ interneuron dysfunction in Alzheimer’s Disease.

My colleagues and I have published an article in Alzheimer’s & Dementia where we demonstrate that a blood-based biomarker, pTau217, can predict brain amyloid levels across a broad spectrum of individuals—from those with no cognitive impairment to those with mild cognitive impairment or dementia. Notably, it can predict a wider range of brain amyloid levels compared to the commonly used cerebrospinal fluid (CSF) biomarker, Ab42/Ab40. The ability to directly predict brain amyloid levels across a wide range makes this blood-based biomarker an invaluable tool for patient screening and monitoring, both in clinical trials and everyday clinical practice. Read the article here: https://lnkd.in/eREvWwme #BBM #PET #diagnosis #monitoring #machinelearning #aiml #alzheimer #biomarker #precisonmedicine #alzheimersdisease #neurology #screening #earlydetection #clinicalpractice #dementia #cognitivedecline #neuroscience

🧠 𝐂𝐚𝐥𝐥 𝐟𝐨𝐫 𝐏𝐚𝐩𝐞𝐫𝐬: Neurology Research Contributions Wanted! 🧠 We are excited to announce a Call for Papers for the upcoming edition of Volume 16, issue 12 focused on 𝐍𝐞𝐮𝐫𝐨𝐥𝐨𝐠𝐲 𝐚𝐧𝐝 𝐍𝐞𝐮𝐫𝐨𝐬𝐜𝐢𝐞𝐧𝐜𝐞. This is a great opportunity to showcase your research, innovative ideas, and findings to a global audience of experts in the field. 🔍 We are looking for submissions on topics including, but not limited to: Neurological disorders (e.g., Alzheimer's, Parkinson's, Stroke, Multiple Sclerosis) 🔸𝐁𝐫𝐚𝐢𝐧 𝐚𝐧𝐝 𝐜𝐨𝐠𝐧𝐢𝐭𝐢𝐯𝐞 𝐟𝐮𝐧𝐜𝐭𝐢𝐨𝐧 🔸𝐍𝐞𝐮𝐫𝐨𝐩𝐥𝐚𝐬𝐭𝐢𝐜𝐢𝐭𝐲 𝐚𝐧𝐝 𝐧𝐞𝐮𝐫𝐨𝐠𝐞𝐧𝐞𝐬𝐢𝐬 🔸𝐍𝐞𝐮𝐫𝐨𝐢𝐦𝐚𝐠𝐢𝐧𝐠 𝐚𝐧𝐝 𝐛𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫𝐬 🔸𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐬 𝐢𝐧 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 🔸𝐍𝐞𝐮𝐫𝐨𝐢𝐧𝐟𝐥𝐚𝐦𝐦𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐧𝐞𝐮𝐫𝐨𝐝𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 🔸𝐏𝐞𝐝𝐢𝐚𝐭𝐫𝐢𝐜 𝐧𝐞𝐮𝐫𝐨𝐥𝐨𝐠𝐲 𝐚𝐧𝐝 𝐧𝐞𝐮𝐫𝐨𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐚𝐥 𝐝𝐢𝐬𝐨𝐫𝐝𝐞𝐫𝐬 📅 Submission Deadline: November 22 2024 🖋️ Submit your paper: https://lnkd.in/gJTrU3A4 (Or) neurology@ecronicon.net This is your chance to contribute to the growing body of knowledge in Neurology and help shape the future of treatments and therapies for neurological conditions. We look forward to receiving your groundbreaking work and connecting with researchers, clinicians, and innovators passionate about advancing neurology! #Neurology #Neuroscience #MedicalResearch #CallForPapers #ResearchOpportunity #Neurobiology #NeurologyConference #ClinicalResearch #Epilepsy #Parkinsonsdisease #Paediatricneurology #Clinicalneuroscience #Behavioralneuroscience #Trauma #Vascularneurology #Neurobiology #StrokeandTraumaticbraininjury #Neuropharmacology #Alzheimersdisease #Migraine #Neuropsychiatry